Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer

2022 ◽  
pp. 107815522110737
Author(s):  
Mustafa Korkmaz ◽  
Engin Hendem ◽  
Melek Karakurt Eryılmaz ◽  
Aykut Demirkıran ◽  
Mustafa Karaağaç ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Nephrotic Syndrome ◽  
Colorectal Adenocarcinoma ◽  
Growth Factor Receptor ◽  
Skin Toxicity ◽  
Dramatic Improvement ◽  
Renal Functions ◽  
Acneiform Rash ◽  
Epidermal Growth ◽  
Cetuximab Therapy

Introduction Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy. Case Report A 58-year-old male patient recently completed cetuximab-based chemotherapy for metastatic colorectal adenocarcinoma. He presented with acute renal failure, anasarca edema and nephrotic proteinuria. The amount of protein in the 24-h urine test was over 15.6 grams. Management & Outcome The patient showed a dramatic improvement in renal function shortly after terminated of cetuximab therapy without immunosuppressive therapy. Discussion Therefore, drugs targeting epidermal growth factor receptor (EGFR) monoclonal antibody were thought to trigger nephrotic syndrome by causing glomerular damage. As a result, physicians using EGFR monoclonal inhibitors should be very careful about renal functions and proteinuria in patients.

Prevention and therapy of acne-like rash in cancer patients receiving therapy with EGFR receptor inhibitors

2020 ◽  
pp. 42-46
Author(s):  
L. S. Kruglova ◽  
I. A. Korolyova ◽  
E. A. Shatokhina
Keyword(s):  
Growth Factor Receptor ◽  
Skin Toxicity ◽  
Well Being ◽  
Social Adaptation ◽  
Acneiform Rash ◽  
Anti Cancer ◽  
Epidermal Growth ◽  
Dermatologic Adverse Events ◽  
Treatment Prognosis

Cancer chemotherapy advanced dramatically. The success in the management of a broad spectrum of malignancies was achieved due to the development of targeted chemotherapeutic drugs, such as inhibitors of the epidermal growth factor receptor (iEGFR). The most common dermatologic side effect of iEGFR therapy is an acneiform rash that occurs in 60–80 % of patients. This adverse event develops during the first 2 weeks of treatment with iEGFR. Diagnostics of acneiform rash may be complicated because of different interpretations by oncologists and dermatologists. Acneiform rash is frequently associated with pain and itch. Skin toxicity affects a patient’s quality of life, including physical and psychological well-being, emotional and social adaptation, may lead to dose reduction and iEGFR discontinuation. The degree of acneiform rash correlates with an iEGFR effectiveness, which is currently confirmed by different data. Thus, the prevention and prompt management of dermatologic adverse events is a pressing issue because they influence the anti-cancer treatment prognosis. This article reviews the current recommendations on the prevention and management of iEGFR associated acneiform rash. The authors present their own clinical case of a patient with acneiform rash during panitumumab (monoclonal antibody against EGFR) therapy.

scholarly journals Papulopustular lesions of the face caused by panitumumab: case report and literature review

2018 ◽  
Vol 24 (2) ◽  
pp. 72-75
Author(s):  
Jonathan Ravasco ◽  
Philippe Lebaud ◽  
Hélène Bodin
Keyword(s):  
Monoclonal Antibody ◽  
Growth Factor Receptor ◽  
Skin Toxicity ◽  
Skin Lesions ◽  
Therapeutic Benefit ◽  
Acute Skin Toxicity ◽  
The Face ◽  
Epidermal Growth ◽  
The Subject ◽  
Dermatologic Adverse Events

Introduction:Panitumumab (VECTIBIX®) is a monoclonal antibody used alone or in combination with a chemotherapy for management of metastatic colorectal cancer.Observation:A patient treated with this protocol manifested skin lesions; the etiological diagnosis was difficult. The lesions, namely a papulopustular rash at the lower third of the face, and the medical history allowed to diagnose an acute skin toxicity case due to this monoclonal antibody.Commentary:Many side effects are related to the panitumumab, among which dermatologic adverse events having already been the subject of some publications. Nevertheless, several studies conclude that the therapeutic benefit of this epidermal growth factor receptor inhibitor makes acceptable these complications.Conclusion:Stop treatment and corticosteroids allowed a whole and quick disappearance of skin lesions. Alongside dermatologists and infectious diseases specialists, the opinion of an oral surgeon was useful to provide an answer to these symptoms.

scholarly journals Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
K. Chanprapaph ◽  
V. Vachiramon ◽  
P. Rattanakaemakorn
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adverse Events ◽  
Current Knowledge ◽  
Growth Factor Receptor ◽  
Skin Toxicity ◽  
Maculopapular Rash ◽  
Postinflammatory Hyperpigmentation ◽  
Epidermal Growth

Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cutaneous adverse events are common due to the interference of epidermal growth factor receptor (EGFR) signaling in the skin. Cutaneous toxicities lead to poor compliance, drug cessation, and psychosocial discomfort. This paper summarizes the current knowledge concerning the presentation and management of skin toxicity from EGFRI. The common dermatologic adverse events are papulopustules and xerosis. Less common findings are paronychia, regulatory abnormalities of hair growth, maculopapular rash, mucositis, and postinflammatory hyperpigmentation. Radiation enhances EGFRI rash due to synergistic toxicity. There is a positive correlation between the occurrence and severity of cutaneous adverse effects and tumor response. To date, prophylactic systemic tetracycline and tetracycline class antibiotics have proven to be the most effective treatment regime.

Antibiotics in prevention of skin toxic reactions of epidermal growth factor receptor inhibitors (literature review)

2021 ◽  
pp. 8-11
Author(s):  
L. S. Kruglova ◽  
I. A. Koroleva
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Topical Therapy ◽  
Growth Factor Receptor ◽  
Skin Toxicity ◽  
Egfr Inhibitors ◽  
Tetracycline Antibiotics ◽  
Negative Effect ◽  
Epidermal Growth

The article is an overview and contains up-to-date information on the use of tetracycline antibiotics in the prevention of acne-like rash in patients receiving therapy with epidermal growth factor receptor inhibitors. According to studies, prevention of skin toxicity is necessary to maintain the effectiveness of the antitumor effect of EGFR inhibitors and to minimize the negative effect of adverse effects from the skin on the quality of life of patients. The use of tetracycline antibiotics in combination with topical therapy and photoprotection for the prevention of acne-like rash against the background of the use of EGFR inhibitors is a fairly safe method for long-term use. Of the antibacterial drugs for the prevention of acne-like rash, the most advisable is the appointment of doxycycline at a dose of 100 mg per day from the first day of taking EGFR inhibitors.

Sign in / Sign up

Export Citation Format

Share Document